Bristol-Myers Squibb CompanyBristol Myers Squibb partnered with Redwire on PIL-BOX missions to study pharmaceutical molecules and crystal growth in microgravity, but no outcome or financial impact is stated.
Redwire Corporation is expanding its microgravity capabilities beyond traditional space missions into scientific research, biotechnology and advanced manufacturing. The company has built a growing microgravity platform with 11 active payload facilities on the International Space Station as of Dec. 31, 2025, and has launched 42 Pharmaceutical In-space Laboratory – Bio-crystal Optimization eXperiment, or PIL-BOX, payloads. During 2025, Redwire entered a licensing agreement with ExesaLibero Pharma under which it is eligible to receive royalties from commercial sales of resulting pharmaceutical products. Bristol Myers Squibb and Eli Lilly have both partnered with Redwire on PIL-BOX missions to study pharmaceutical molecules and crystal growth in microgravity. The Zacks Consensus Estimate for 2026 and 2027 earnings per share suggests year-over-year growth of 57.32% and 40%, respectively, while Redwire trades at a forward 12-month price-to-sales of 4.92X versus an industry average of 2.29X.
Bristol-Myers Squibb CompanyBristol Myers Squibb partnered with Redwire on PIL-BOX missions to study pharmaceutical molecules and crystal growth in microgravity, but no outcome or financial impact is stated.
Eli Lilly and CompanyEli Lilly partnered with Redwire on PIL-BOX missions to study pharmaceutical molecules and crystal growth in microgravity, but no outcome or financial impact is stated.
Redwire CorpRedwire's licensing agreement with ExesaLibero Pharma makes it eligible for royalties from commercial sales of resulting pharmaceutical products.
ExesaLibero Pharma entered a licensing agreement with Redwire under which Redwire receives royalties from commercial sales of resulting pharmaceutical products.